L G Rubin1, D Voulalas, L Carmody. 1. Department of Pediatrics, Schneider Children's Hospital of Long Island Jewish Medical Center, New Hyde Park, NY 11042.
Abstract
OBJECTIVE: To determine the safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with sickle cell disease. RESEARCH DESIGN: Prospective, nonrandomized, nonblinded study. SETTING: Hospital-based, comprehensive sickle cell center. PATIENTS: Children with sickle cell disease aged 18 months to 18 years who were previously unvaccinated or had an inadequate or waning response to H influenzae type b polysaccharide vaccine. SELECTION PROCEDURES: Consecutive eligible patients. INTERVENTIONS: Vaccination and observation for adverse effects. Blood samples were taken before and 1 to 2 and 6 months after vaccination to measure anticapsular antibody levels. MEASUREMENTS AND RESULTS: Vaccination was well tolerated. One hundred percent and 96% of the 31 immunized children had postvaccination anticapsular antibody concentrations of greater than 0.15 and 1.0 mg/L, respectively. Six months after vaccination, 100% and 89% of children had these antibody concentrations. CONCLUSIONS: H influenzae type b conjugate vaccines are safe and highly immunogenic in children with sickle cell disease. It is likely that these vaccines will be protective against invasive H influenzae type b disease.
OBJECTIVE: To determine the safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine in children with sickle cell disease. RESEARCH DESIGN: Prospective, nonrandomized, nonblinded study. SETTING: Hospital-based, comprehensive sickle cell center. PATIENTS: Children with sickle cell disease aged 18 months to 18 years who were previously unvaccinated or had an inadequate or waning response to H influenzae type b polysaccharide vaccine. SELECTION PROCEDURES: Consecutive eligible patients. INTERVENTIONS: Vaccination and observation for adverse effects. Blood samples were taken before and 1 to 2 and 6 months after vaccination to measure anticapsular antibody levels. MEASUREMENTS AND RESULTS: Vaccination was well tolerated. One hundred percent and 96% of the 31 immunized children had postvaccination anticapsular antibody concentrations of greater than 0.15 and 1.0 mg/L, respectively. Six months after vaccination, 100% and 89% of children had these antibody concentrations. CONCLUSIONS: H influenzae type b conjugate vaccines are safe and highly immunogenic in children with sickle cell disease. It is likely that these vaccines will be protective against invasive H influenzae type b disease.
Authors: Thomas N Williams; Sophie Uyoga; Alex Macharia; Carolyne Ndila; Charlotte F McAuley; Daniel H Opi; Salim Mwarumba; Julie Makani; Albert Komba; Moses N Ndiritu; Shahnaaz K Sharif; Kevin Marsh; James A Berkley; J Anthony G Scott Journal: Lancet Date: 2009-09-09 Impact factor: 79.321